Who bought whom, for how much, and what the buyer was paying for. Device startup exits, with the terms where they are public.
| Date | Acquirer | Target | Price | Terms | Status |
|---|---|---|---|---|---|
| Oct 16, 26 | MiMedx | Sanara MedTech | $350M | $33.00 in cash plus 0.4735 MiMedx shares for each Sanara share, about $35 a share | Announced July 30, 2026, FTC second request October 15, 2026 |
| Oct 15, 26 | Labcorp | BioReference Health lab testing businesses | Up to $872M | $722M upfront plus up to $150M tied to 4Kscore revenue | Announced October 15, 2026 |
| Oct 15, 26 | Medtronic shareholders | MiniMed | Undisclosed | Medtronic exchanged 252,813,348 MiniMed shares for 55,032,401 of its own ordinary shares at a ratio of 4.5939 | Closed October 15, 2026 |
| Oct 13, 26 | Johnson & Johnson | DePuy Synthes | Undisclosed | Separation of the orthopedics unit, which executives now say is more likely a spin-off than a sale | Targeted for mid-2027 |
| Oct 13, 26 | Agilent Technologies | Proscia | $240M | $240M cash upfront plus up to $30M in performance milestones | Announced October 13, 2026, expected to close early in Agilent fiscal 2027 |
| Oct 12, 26 | Stryker | CMR Surgical | $400M for an equity stake | Exclusive option to acquire 100 percent of CMR equity, plus exclusive US sales agency for the Versius portfolio | Announced October 12, 2026 |
| Oct 12, 26 | STERIS | Xodus Medical | $2.1B | $2.1B cash at closing plus up to $150M tied to calendar 2028 performance targets, financed primarily with debt | Announced October 12, 2026 |
| Oct 9, 26 | Carrot | GreenMan Vision | Undisclosed | Announced October 9, 2026 | |
| Oct 6, 26 | iRhythm Technologies | VitalConnect | $287.5M | $237.5M cash plus about 423,334 iRhythm shares, with $10M of working capital funding between signing and close | Closed October 6, 2026 |
| Oct 5, 26 | GE HealthCare | Sofie Biosciences | $945M | All cash | Announced October 5, 2026, expected to close in the first half of 2027 |
| Oct 1, 26 | Surmodics | Alta Biomed | Undisclosed | Closed October 1, 2026 | |
| Oct 1, 26 | Wandercraft | Ekso Bionics | Undisclosed | Closed October 1, 2026 | |
| Oct 1, 26 | Axogen | BioCircuit Technologies | $200M | All cash | Closed October 1, 2026 |
| Sep 30, 26 | Terumo Neuro | Arsenal Medical | Undisclosed | Announced September 30, 2026 | |
| Sep 28, 26 | Webster Equity Partners | Lifecore Biomedical | Up to $663.7M | $6.28 per share in cash plus non-tradable CVRs worth up to $3.39 more per share | Announced September 28, 2026 |
| Sep 15, 26 | Ambu | TIMS Medical | Up to $65M | $45M cash upfront plus up to $20M in milestones | Announced September 15, 2026 |
| Sep 14, 26 | Medtronic shareholders | MiniMed | Undisclosed | Exchange offer: about $107.53 of MiniMed stock for every $100 of Medtronic stock, a 7 percent discount | Announced September 14, 2026, expires October 9, 2026 |
| Sep 13, 26 | GE HealthCare | Sofie Biosciences | About $1B | Reported in advanced talks, September 13, 2026 | |
| Sep 11, 26 | Jaguar LAA | Laminar program assets (Johnson & Johnson) | Undisclosed | Announced September 11, 2026 | |
| Sep 11, 26 | Apollo Global Management | DePuy Synthes (Johnson & Johnson) | About $20B | In talks, reported September 11, 2026 |
MiMedx and Sanara MedTech received FTC second requests on October 15 over the $350M cash and stock merger announced in July. The Hart-Scott-Rodino waiting period now runs 30 days past substantial compliance.
Labcorp agreed to buy clinical, women's health, urology and correctional testing businesses from Opko Health's BioReference Health for $722M upfront and up to $150M more tied to 4Kscore revenue.
Medtronic reported final results of its MiniMed exchange offer on October 14 and now holds no stake in the diabetes business. MiniMed opened October 15 as an independent company on Nasdaq under MMED.
Johnson & Johnson plans to separate DePuy Synthes by mid-2027 and now calls a spin-off more likely than a sale. MedTech sales reached $8.64B in the third quarter, up 2.5 percent and short of the $8.74B consensus.
Agilent Technologies agreed on October 13 to buy digital pathology company Proscia for $240 million in cash, with up to $30 million more tied to milestones. The deal is expected to close early in Agilent fiscal 2027.
Stryker invested about $400 million in CMR Surgical on October 12 and took an exclusive option to acquire all of the Cambridge robotics company. Stryker also becomes the exclusive US sales agent for the Versius portfolio.
STERIS agreed on October 12 to buy Xodus Medical for $2.1 billion at closing, with up to $150 million more tied to 2028 targets. Xodus projects about $245 million in calendar 2026 revenue from operating room consumables.
Carrot agreed on October 9, 2026 to acquire GreenMan Vision and its InSightVR cataract lens simulator. Terms were not disclosed.
iRhythm Technologies closed its purchase of VitalConnect on October 6, 2026 for $287.5 million. The company paid $237.5 million in cash and issued about 423,334 shares at closing.
GE HealthCare agreed on October 5 to buy Sofie Biosciences for $945 million in cash. The deal brings 15 US contract manufacturing sites for PET radiopharmaceuticals and is expected to close in the first half of 2027.
Surmodics acquired Alta Biomed and its PzF thin film surface coating, announced October 1, with terms undisclosed. Surmodics has taken over Alta's testing operations in Carlsbad, California.
Wandercraft signed and closed its purchase of Ekso Bionics from ChronoScale Holdings on October 1. Terms were not disclosed. The combined company owns four exoskeletons and reaches more than 700 rehabilitation centers.
Axogen completed its $200M cash acquisition of BioCircuit Technologies on October 1, three weeks after announcing it. Axogen expects NerveTape to add about $6M to fourth quarter revenue and about $34M in 2027.
Terumo Neuro agreed on September 30 to acquire Arsenal Medical and NeoCast, its liquid embolic for chronic subdural hematoma. Terms were not disclosed.
Webster Equity Partners agreed on September 28 to buy Lifecore Biomedical for $6.28 a share in cash, a 49.5 percent premium. Contingent value rights could take the total to $663.7 million.
Ambu agreed to buy TIMS Medical for $45 million in cash with up to $20 million more in milestones. The deal brings roughly 7,000 US hospital installations of endoscopy imaging and reporting software.
Medtronic launched an exchange offer on September 14 covering 80.1% of MiniMed's common stock. Holders get about $107.53 in MiniMed shares for every $100 of Medtronic stock, and the offer runs through October 9, 2026.
The Financial Times reported on September 13, 2026 that GE HealthCare is in advanced talks to buy PET radiopharmaceutical maker Sofie Biosciences for about $1 billion. Neither company has commented and no deal has been announced.
Jaguar LAA, formed and financed by Sante Ventures, has acquired the Laminar left atrial appendage assets from Johnson & Johnson for undisclosed terms. J&J paid $400 million upfront for Laminar in November 2023.
Bloomberg reported on September 11 that Apollo Global Management is negotiating to buy Johnson & Johnson's orthopedics unit for close to $20 billion. J&J had said it would spin the business off instead.
Velosity acquired Lucid Labs, a Rogers, Minnesota design and prototyping firm founded in 2004, in a deal announced September 11, 2026. Terms were not disclosed. Lucid brings more than 20 design and development engineers focused on embedded medical device work.
Axogen agreed on September 10 to buy Atlanta-based BioCircuit Technologies for $200 million in cash. BioCircuit sells NerveTape, cleared under K233533 in February 2024 as a sutureless way to repair transected nerves.
Precera Medical acquired Additive Metal Services of Port Huron, Michigan on September 10 for undisclosed terms. It is the first deal for Precera, the contract manufacturer SK Capital carved out of LISI Group's medical division in November 2025.
Stryker agreed on September 1, 2026 to acquire ZuriMED, the Zurich company behind the FiberLocker rotator cuff augmentation patch FDA cleared in late 2024 under K241219. Terms were not disclosed.
Enovis signed a binding offer on September 1, 2026 to acquire Grenoble surgical robotics company eCential Robotics for 155 million euros, plus up to 35 million euros in milestone payments. The deal is expected to close at the end of 2026.
iRhythm Technologies agreed on August 10, 2026 to acquire VitalConnect, maker of the VitalPatch wearable monitor, for $287.5 million. The deal is expected to close by the end of 2026 and gives iRhythm the parts of the mobile cardiac telemetry market its Zio devices do not reach.
Medtronic completed its acquisition of SPR Therapeutics on July 17, 2026, paying $650 million in cash for the maker of the Sprint peripheral nerve stimulation system. The deal, announced May 20, is Medtronic's third device acquisition of 2026.
DePuy Synthes agreed on July 16, 2026 to acquire Expanding Innovations, whose expandable interbody cages for lumbar fusion lock without screws. Terms were not disclosed. The buyer plans to pair the implants with its Velys robot.
Stereotaxis completed its acquisition of French vascular robotics company Robocath on July 9, 2026: $20 million in cash upfront and up to $25 million more in milestones tied to regulatory approvals and commercial targets, including FDA clearance of Robocath's next-generation system.
Resmed completed its $340 million acquisition of Noctrix Health on June 1, 2026. Noctrix makes Nidra, a wearable nerve stimulation device for restless legs syndrome that FDA authorized through De Novo DEN220059 in 2023.
Olympus agreed on May 26, 2026 to acquire Israel's BioProtect for $270 million. BioProtect's biodegradable balloon spacer protects healthy tissue during prostate cancer radiation therapy and has been used in more than 11,000 procedures since its 2023 launch.
Stryker agreed on April 13, 2026 to acquire Amplitude Vascular Systems, then disclosed in a May 11 SEC filing that the deal is worth up to $835 million: about $435 million in cash plus up to $400 million in milestones. The Waltham company's Pulse IVL system is still investigational.
Johnson & Johnson agreed on April 27, 2026 to acquire Atraverse Medical, the Cardiff by the Sea company behind the Hotwire radiofrequency guidewire for left-heart access. Terms were not disclosed and the deal was expected to close in the second quarter of 2026.
New clearances, funding rounds and regulatory moves for device founders, and every new how-to guide and template as it lands. No noise, no login.
You're in. The next morning brief lands in your inbox.